PRME (Prime Medicine) Beneish M-Score : 0.00 (As of Dec. 12, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Prime Medicine's Beneish M-Score or its related term are showing as below:

During the past 4 years, the highest Beneish M-Score of Prime Medicine was 0.00. The lowest was 0.00. And the median was 0.00.

Prime Medicine Beneish M-Score Historical Data

The historical data trend for Prime Medicine's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Beneish M-Score Chart

Prime Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Prime Medicine Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beneish M-Score	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Prime Medicine's Beneish M-Score

For the Biotechnology subindustry, Prime Medicine's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prime Medicine's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Prime Medicine's Beneish M-Score falls into.

Prime Medicine Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Prime Medicine for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Sep24) TTM:

Last Year (Sep23) TTM:

Total Receivables was $55.00 Mil.
Revenue was 0.209 + 0 + 0.591 + 0 = $0.80 Mil.
Gross Profit was 0.209 + 0 + 0.591 + 0 = $0.80 Mil.
Total Current Assets was $246.07 Mil.
Total Assets was $332.78 Mil.
Property, Plant and Equipment(Net PPE) was $72.65 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.66 Mil.
Selling, General, & Admin. Expense(SGA) was $50.94 Mil.
Total Current Liabilities was $37.88 Mil.
Long-Term Debt & Capital Lease Obligation was $36.76 Mil.
Net Income was -52.518 + -55.327 + -45.761 + -65.643 = $-219.25 Mil.
Non Operating Income was 1.017 + -0.4 + 2.714 + -8.78 = $-5.45 Mil.
Cash Flow from Operations was -25.912 + -45.491 + -67.707 + -43.864 = $-182.97 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $184.53 Mil.
Total Assets was $239.15 Mil.
Property, Plant and Equipment(Net PPE) was $39.30 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.28 Mil.
Selling, General, & Admin. Expense(SGA) was $39.93 Mil.
Total Current Liabilities was $39.37 Mil.
Long-Term Debt & Capital Lease Obligation was $5.82 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(55 / 0.8)	/	(0 / 0)
	=	68.75	/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0.8 / 0.8)
	=		/	1
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (246.071 + 72.651) / 332.784)	/	(1 - (184.531 + 39.302) / 239.145)
	=	0.042256	/	0.064028
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0.8	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(4.276 / (4.276 + 39.302))	/	(5.658 / (5.658 + 72.651))
	=	0.098123	/	0.072252
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(50.944 / 0.8)	/	(39.929 / 0)
	=	63.68	/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((36.764 + 37.877) / 332.784)	/	((5.822 + 39.366) / 239.145)
	=	0.224293	/	0.188956
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-219.249 - -5.449	-	-182.974)	/	332.784
	=	-0.092631

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Prime Medicine Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Prime Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Erie Street, Cambridge, MA, USA, 02139

Website

https://www.primemedicine.com

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Executives

Robert Nelsen	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill	director	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson	officer: See Remarks	88 SIDNEY STREET, CAMBRIDGE MA 02139
Meredith Goldwasser	officer: SVP, Strategy & Corporate Ops.	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Jeremy Duffield	officer: Chief Scientific Officer	PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139